Surgery Partners (NASDAQ: SGRY) saw its stock plummet by nearly 25% following its latest quarterly earnings release, a stark contrast to the S&P 500 index’s 1.5% growth. The company reported revenue of $821.5 million, up nearly 7% year-over-year, but net income dropped 31% to $16.5 million or $0.13 per share.

Analysts were expecting slightly higher revenue and significantly higher non-GAAP earnings from Surgery Partners. The company attributed its revenue growth to orthopedic procedures but faced challenges with volume and payer mix trends.

Surgery Partners also fell short on full-year revenue guidance, expecting just under $3.3 billion for 2025 compared to analyst consensus of over $3.35 billion. Management is projecting EBITDA of $535 million to $540 million.

The Motley Fool’s Stock Advisor team did not include Surgery Partners in their list of the 10 best stocks to buy now. The stocks chosen by the team historically have produced significant returns, outperforming the S&P 500 by a wide margin. Join the investing community for more insights.

Read more at Yahoo Finance: Why Surgery Partners Stock Plummeted on Monday